The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia
Open accessAbstract
BACKGROUND: The high prevalence of methicillin-resistant S. aureus (MRSA) has led clinicians to select antibiotics that have coverage against MRSA, usually vancomycin, for empiric therapy for suspected staphylococcal infections. Clinicians often continue vancomycin started empirically even when methicillin-susceptible S. aureus (MSSA) strains are identified by culture. However, vancomycin has been associated with poor outcomes such as nephrotoxicity, persistent bacteremia and treatment failure. The objective of this study was to compare the effectiveness of vancomycin versus the beta-lactam antibiotics nafcillin and cefazolin among patients with MSSA bacteremia. The outcome of interest for this study was 30-day in-hospital mortality. METHODS: This retrospective cohort study included all adult in-patients admitted to a tertiary-care facility between January 1, 2003 and June 30, 2007 who had a positive blood culture for MSSA and received nafcillin, cefazolin or vancomycin. Cox proportional hazard models were used to assess independent mortality hazards comparing nafcillin or cefazolin versus vancomycin. Similar methods were used to estimate the survival benefits of switching from vancomycin to nafcillin or cefazolin versus leaving patients on vancomycin. Each model included statistical adjustment using propensity scores which contained variables associated with an increased propensity to receive vancomycin. RESULTS: 267 patients were included; 14% (38/267) received nafcillin or cefazolin, 51% (135/267) received both vancomycin and either nafcillin or cefazolin, and 35% (94/267) received vancomycin. Thirty (11%) died within 30 days. Those receiving nafcillin or cefazolin had 79% lower mortality hazards compared with those who received vancomycin alone (adjusted hazard ratio (HR): 0.21; 95% confidence interval (CI): 0.09, 0.47). Among the 122 patients who initially received vancomycin empirically, those who were switched to nafcillin or cefazolin (66/122) had 69% lower mortality hazards (adjusted HR: 0.31; 95% CI: 0.10, 0.95) compared to those who remained on vancomycin. CONCLUSIONS: Receipt of nafcillin or cefazolin was protective against mortality compared to vancomycin even when therapy was altered after culture results identified MSSA. Convenience of vancomycin dosing may not outweigh the potential benefits of nafcillin or cefazolin in the treatment of MSSA bacteremia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationThe APACHE III Prognostic System
Knaus, W. A., Wagner, D. P., Draper, E. A., Zimmerman, J. E., Bergner, M., Bastos, P. G., Sirio, C. A., Murphy, D. J., Lotring, T., Damiano, A., et al. (1991) · Chest · doi:10.1378/chest.100.6.1619 · Cited by 3,439
The APACHE III Prognostic System
Teres, D., & Lemeshow, S. (1992) · Chest · doi:10.1378/chest.102.6.1919b · Cited by 2,880
Cosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/345476 · Cited by 1,964
Self-citationLodise, T. P., Lomaestro, B., Graves, J., & Drusano, G. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01602-07 · Cited by 574
Chang, F.-Y., Peacock, J. E., Musher, D. M., Triplett, P., MacDonald, B. B., Mylotte, J. M., O’Donnell, A., Wagener, M. M., & Yu, V. L. (2003) · Medicine · doi:10.1097/01.md.0000091184.93122.09 · Cited by 530
Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era
DeLeo, F. R., & Chambers, H. F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38226 · Cited by 512
Multidrug-resistant Acinetobacter Infection Mortality Rate and Length of Hospitalization
Sunenshine, R. H., Wright, M.-O., Maragakis, L. L., Harris, A. D., Song, X., Hebden, J., Cosgrove, S. E., Anderson, A., Carnell, J., Jernigan, D. B., et al. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1301.060716 · Cited by 411
Self-citationGonzalez, C., Rubio, M., Romero-Vivas, J., Gonzalez, M., & Picazo, J. J. (1999) · Clinical Infectious Diseases · doi:10.1086/313440 · Cited by 407
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Simonsen, K. A., Anderson-Berry, A. L., Delair, S. F., & Davies, H. D. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-13 · Cited by 984
Clinical Management of Staphylococcus aureus Bacteremia: A Review
Holland, T. L., Arnold, C., & Fowler, V. G. (2014) · JAMA · doi:10.1001/jama.2014.9743 · Cited by 449
Bai, A. D., Showler, A., Burry, L., Steinberg, M., Ricciuto, D. R., Fernandes, T., Chiu, A., Raybardhan, S., Science, M., Fernando, E., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ120 · Cited by 254
The Empirical Combination of Vancomycin and a -Lactam for Staphylococcal Bacteremia
McConeghy, K. W., Bleasdale, S. C., & Rodvold, K. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit560 · Cited by 90
Metadata
- Authors
- Schweizer, M. L., Furuno, J. P., Harris, A. D., Johnson, J. K., Shardell, M. D., McGregor, J. C., Thom, K. A., Cosgrove, S. E., Sakoulas, G., & Perencevich, E. N.
- Venue
- BMC Infectious Diseases
- Published
- 2011-10-19
- Volume
- 11
- Issue
- 1
- Pages
- 279-279
- ISSN
- 1471-2334 (ISSN-L)
- OpenAlex
- W2045190713
- Cited by
- 254
- References
- 29
- FWCI
- 9.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. https://app.cochat.ai/papers/10.1186/1471-2334-11-279
- The paper
- Schweizer, M. L., Furuno, J. P., Harris, A. D., Johnson, J. K., Shardell, M. D., McGregor, J. C., Thom, K. A., Cosgrove, S. E., Sakoulas, G., & Perencevich, E. N. (2011). Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infectious Diseases. https://doi.org/10.1186/1471-2334-11-279
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.